$MAIA Biotechnology (MAIA.US)$ (RTTNews) - MAIA Biotechnology, Inc. (MAIA) announced the FDA has cleared Investigational New Drug application for THIO to be evaluated in the U.S. as part of THIO-101, the company's ongoing global phase 2 clinical study in patients with advanced Non-Small Cell Lung Cancer. THIO is being tested in sequential combination with Regeneron's anti PD-1 monoclonal antibody cemiplimab to evaluate anti-tumor activity and immune response in...
$Novo Integrated Sciences(NVOS.US$ 諾和綜合科技獲得了 10 億美元的主抵押品轉讓協議,它表示將滿足其未來 15 年的資本要求。首席執行官羅伯特·馬塔基奧內(Robert Mattacchione)表示,該協議將使醫療保健公司能夠實現其國際增長股份超過一倍至 43 美分。
已翻譯